Patients travelling to Dubai for medical treatment could soon enjoy a faster and more seamless experience under a new partnership between the General Directorate of Identity and Foreigners Affairs (GDRFA Dubai) and the Dubai Health Authority (DHA).

The two entities have signed an agreement aimed at streamlining medical visa procedures and improving the patient journey from arrival to recovery.

Under the partnership, healthcare and residency services will be more closely integrated, making it easier for international patients to access treatment in Dubai. The initiative will also strengthen coordination between visa processing, healthcare providers and insurance systems.

A key focus is on enhancing digital integration between the two organisations, allowing medical visa applications to be processed more efficiently through the Dubai Health Experience network.

Officials said the collaboration could pave the way for future innovations, including a smart medical visa and proactive digital services designed to support patients throughout their treatment journey.

Lieutenant General Mohammed Ahmed Al Marri, Director General of GDRFA Dubai, said the partnership reflects Dubai’s vision of creating connected government services that put people first.

Meanwhile, Dr Alawi Sheikh Ali, Director General of the DHA, said health tourism is about more than medical care, adding that accessibility, convenience and quality of service are equally important parts of the patient experience.

The initiative supports Dubai’s broader ambitions to strengthen its position as a global healthcare and medical tourism destination while delivering faster, smarter and more integrated services for visitors seeking treatment in the emirate.

UAE authorities have issued an urgent recall of two insecticide products marketed under the Goodbye All Insects brand after identifying multiple regulatory and safety concerns, including the presence of a prohibited substance in one of the products

The action was announced by the Emirates Drug Establishment (EDE), which said the recall forms part of its ongoing efforts to protect consumers and ensure that products available in the UAE market meet approved health, safety and regulatory standards.

The products affected by the recall are Goodbye All Insects Max Kills in One Spray and Goodbye All Insects Spray, both manufactured by SCITRA.

According to the EDE, investigations uncovered regulatory and technical violations linked to the sale and distribution of products that had not been officially registered with the authority. Registration is a key requirement designed to ensure that products undergo the necessary evaluation before reaching consumers.

Product does not comply with specifications

In addition to the registration issues, the authority found discrepancies in the concentration levels of active ingredients in one of the insecticides. Officials said the product did not comply with approved specifications or relevant international standards, raising concerns about quality and consistency.

More significantly, one of the recalled products was found to contain a prohibited substance. As a result, authorities ordered its immediate removal from the market to prevent further distribution and reduce any potential risk to public health.

The Emirates Drug Establishment said it is working closely with regulatory agencies and relevant authorities across the UAE to ensure the affected products are removed from retail stores, distribution channels and online marketplaces in accordance with established regulatory procedures.

Consumers urged to stop using products

Consumers who have already purchased either product have been strongly advised to stop using them immediately. Authorities also urged the public not to buy, sell or distribute the recalled products and to follow official guidance issued by relevant government entities.

The Emirates Drug Establishment reaffirmed its commitment to transparency, proactive risk management and rapid response measures when potential safety concerns are identified. Officials added that cooperation with local regulatory partners remains a key part of efforts to safeguard public health and ensure only safe, compliant products remain available in the UAE market.

Residents are encouraged to stay informed through official announcements and report any concerns regarding recalled or non-compliant products to the relevant authorities.

The Emirates Drug Establishment has announced a major reduction in the retail prices of 168 pharmaceutical products across the UAE, delivering significant savings on medications used to treat chronic and life-threatening illnesses.

The revised pricing decision will officially take effect on May 30 and covers a broad range of treatments, including medicines for heart disease, diabetes, hypertension, cancer, stroke prevention, cholesterol disorders, respiratory illnesses, neurological conditions, mental health disorders and eye diseases.

Pharmacies across the UAE have already begun updating their pricing systems ahead of implementation, with reductions varying depending on the type of medication and therapeutic category.

According to the new pricing structure, discounts range from around 5 per cent to nearly 60 per cent for some of the country’s most expensive vital and biologic medicines.

Lower price for cholesterol medicine

One of the biggest reductions applies to Zocor 40mg, a cholesterol-lowering drug whose price has been reduced by approximately 59.5 per cent. Meanwhile, Xalatan, used to treat elevated eye pressure in glaucoma patients, recorded a price cut of more than 51 per cent.

Several high-cost cancer and biologic treatments also saw major reductions under the new decision. The lung cancer medication Alunbrig 180mg was reduced from Dh26,433 to Dh21,108, while the 90mg version dropped from Dh19,824 to Dh12,520. The 30mg dosage also saw a significant reduction, falling from Dh6,608 to Dh4,173.

In another major adjustment, Xeloda 150mg, commonly prescribed for breast, colon and rectal cancer, was reduced from Dh347 to Dh241.

The latest move is expected to provide substantial relief for patients requiring long-term treatment, particularly those dependent on expensive speciality medications and biologic therapies.